Secondary Antibodies Market Report 2026

The secondary antibodies market size has grown strongly in recent years. It will grow from $1.99 billion in 2025 to $2.19 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growth in immunoassay-based research, expansion of life science laboratories, increasing use of western blotting and ELISA, advancements in antibody purification technologies, rising biomedical research funding.

The secondary antibodies market size is expected to see strong growth in the next few years. It will grow to $3.15 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing demand for high-throughput diagnostics, expansion of precision medicine research, rising investments in proteomics and genomics, growing adoption of automated assay platforms, innovation in antibody engineering. Major trends in the forecast period include increasing demand for highly cross-adsorbed secondary antibodies, rising use of fluorophore-conjugated antibodies, growing adoption in multiplex assays, expansion of recombinant secondary antibody production, enhanced focus on signal sensitivity and specificity.

The rising prevalence of chronic diseases is expected to drive the growth of the secondary antibodies market in the coming years. Chronic diseases are long-lasting health conditions that develop gradually and often require ongoing medical care. The increase in these diseases is partly due to sedentary lifestyles, as prolonged inactivity raises the risk of conditions such as heart disease and diabetes. Secondary antibodies support chronic disease management by enabling precise detection of biomarkers, making them essential for diagnostic assays and monitoring disease progression. They enhance assay sensitivity and specificity, supporting timely and accurate treatment decisions. For example, in June 2024, the National Health Service, a UK-based government department, reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from 3,065,825 cases in 2022. Consequently, the rising prevalence of chronic diseases is propelling the secondary antibodies market.

Major companies in the secondary antibodies market are focusing on advanced products, such as recombinant monoclonal antibodies, to improve experimental reproducibility, specificity, and reduce lot-to-lot variability. Recombinant monoclonal antibodies are produced in controlled cell-line systems using genetically defined sequences, ensuring high consistency and virtually unlimited supply. For instance, in October 2023, Proteintech Group Inc., a US-based manufacturer of antibodies, proteins, and ELISA kits, launched Multi-rAb Recombinant Secondary Antibodies. These antibodies provide more consistent and reproducible performance compared to traditional animal-derived antibodies, delivering stronger and cleaner signal detection in immunoassays. This enables researchers to visualize low-abundance targets with higher clarity, improving accuracy and reproducibility in applications such as immunofluorescence and western blotting, and supporting more reliable scientific conclusions.

In September 2024, Leinco Technologies Inc., a US-based biotechnology company, acquired QED Bioscience Inc. for an undisclosed amount. This acquisition allows Leinco Technologies to expand its antibody capabilities and product portfolio to better serve research and diagnostic markets globally. QED Bioscience Inc., also based in the US, develops secondary antibodies and related immunoassay reagents.

Major companies operating in the secondary antibodies market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Bio-Techne Corporation, Miltenyi Biotec GmbH, GenScript Biotech Corporation, Promega Corporation, Sino Biological Inc., Cell Signaling Technology Inc., Fortis Life Sciences, OriGene Technologies Inc., Becton Dickinson and Company, GeneTex Inc., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Creative Diagnostics Inc., Jackson ImmunoResearch Laboratories Inc., SouthernBiotech LLC, MyBioSource Inc., Biotium Inc.

North America was the largest region in the secondary antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the secondary antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the secondary antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the secondary antibodies market by increasing costs of imported biological reagents, conjugation chemicals, purification equipment, and cold-chain logistics components. Research laboratories and diagnostic centers in North America and Europe are most affected due to reliance on specialized imported antibodies, while Asia-Pacific faces pricing pressure on export-oriented production. These tariffs are raising reagent costs and impacting research budgets. However, they are also encouraging domestic antibody production, regional reagent manufacturing, and local supply chain strengthening.

The secondary antibodies market research report is one of a series of new reports that provides secondary antibodies market statistics, including secondary antibodies industry global market size, regional shares, competitors with a secondary antibodies market share, detailed secondary antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the secondary antibodies industry. This secondary antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Secondary antibodies are antibodies that specifically bind to the constant regions of primary antibodies in a species- and isotype-specific manner and are often conjugated to reporter molecules for detection. They convert primary antibody binding into a visible, fluorescent, or enzymatic signal, enabling the detection, visualization, or quantification of target antigens.

The main product types of secondary antibodies include monoclonal, polyclonal, and others. Monoclonal secondary antibodies are produced from a single cloned immune cell and recognize only one specific epitope on an antigen. These antibodies are generated in various host species such as goat, rabbit, donkey, mouse, and others, and are available in multiple conjugate types, including enzyme-conjugated, fluorophore-conjugated, unconjugated, and more. They are used in applications such as western blotting, immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), flow cytometry, and others, serving end users including pharmaceutical and biotechnology companies, academic and research institutions, hospitals and diagnostic centers, and contract research organizations (CROs).

The secondary antibodies consists of sales of labeled antibodies, unlabeled antibodies, fragment antibodies, conjugated antibodies, fluorescently-labeled antibodies, and biotinylated antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.